US2022056456A1PendingUtilityA1

Means and methods for reducing tumorigenicity of cancer stem cells

71
Assignee: B G NEGEV TECHNOLOGIES AND APPLICATIONS LTD AT BEN GURION UNIVPriority: Nov 10, 2015Filed: Nov 12, 2021Published: Feb 24, 2022
Est. expiryNov 10, 2035(~9.3 yrs left)· nominal 20-yr term from priority
Inventors:Varda Shoshan-Barmatz
C12Q 1/68A61P 35/00C12N 15/1138C12Q 2600/158C12N 2310/14A61K 31/713C12Q 1/6886C12Q 2600/118
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention discloses the use of RNA inhibitory molecules, particularly siRNA molecules silencing the expression of Voltage-Dependent Ion Chanel-1 (VDAC1) for the induction of cancer stem cell differentiation and reduction of TAMS abundance and tumor angiogenesis, thereby preventing tumor invention and recurrence.

Claims

exact text as granted — not AI-modified
1 . A voltage dependent anion channel 1 (VDAC1)-silencing oligonucleotide comprising the nucleic acid sequence set forth in SEQ ID NO:10. 
     
     
         2 . The VDAC1-silencing oligonucleotide of  claim 1 , wherein said VDAC1-silencing oligonucleotide consists of the nucleic acid sequence set forth in SEQ ID NO:10. 
     
     
         3 . The VDAC1-silencing oligonucleotide of  claim 1 , wherein said VDAC1-silencing oligonucleotide is a double stranded (ds) RNA molecule comprising a first oligonucleotide having the nucleic acid sequence set forth in SEQ ID NO:10 and a second oligonucleotide essentially complementary thereto. 
     
     
         4 . The VDAC1-silencing oligonucleotide of  claim 3 , wherein said VDAC1-silencing oligonucleotide is a double stranded (ds) RNA molecule comprising a first oligonucleotide having the nucleic acid sequence set forth in SEQ ID NO:10 and a second oligonucleotide having the nucleic acid sequence set forth in SEQ ID NO:13. 
     
     
         5 . The VDAC1-silencing oligonucleotide of  claim 4 , wherein said VDAC1-silencing oligonucleotide is a double stranded (ds) RNA molecule comprising a first oligonucleotide consisting of the nucleic acid sequence set forth in SEQ ID NO:10 and a second oligonucleotide consisting of the nucleic acid sequence set forth in SEQ ID NO:13. 
     
     
         6 . A construct comprising the VDAC-1 silencing oligonucleotide of  claim 1 .

Join the waitlist — get patent alerts

Track US2022056456A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.